Abstracts tagged "Psoriatic arthritis"

Abstract Number: 2613 • 2018 ACR/ARHP Annual Meeting
Patterns of Medication Use in a Validated Cohort of Psoriatic Arthritis (PsA) Patients
Madeline J. Epsten¹, Lisa A. Mandl¹, Jackie Szymonifka² and Sergio Schwartzman¹, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York, NY
Background/Purpose: There is currently a lack of consensus among experts on the optimal therapeutic management of psoriatic arthritis (PsA). EULAR and GRAPPA recommendations support initial…
Abstract Number: 1591 • 2018 ACR/ARHP Annual Meeting
Is Enthesitis a Marker of Disease Severity in Early Psoriatic Arthritis?
Lihi Eder¹, Chandra Farrer² and Dana Jerome³, ¹Women's College Research Institute, University of Toronto, Women's College Hospital, Toronto, ON, Canada, ²Rheumatology, Women's College Hospital, Toronto, ON, Canada, ³University of Toronto, Women's College Hospital, Toronto, ON, Canada
Background/Purpose: Enthesitis is a key feature in psoriatic arthritis (PsA) affecting approximately a third of the patients. Ultrasound improves the detection of enthesitis compared to…
Abstract Number: 2831 • 2018 ACR/ARHP Annual Meeting
High Need for Anti-TNF Therapy after Withdrawal Strategy in Early Peripheral Spondyloarthritis
Philippe Carron¹, Gaëlle Varkas², Thomas Renson³, Roos Colman⁴, Dirk Elewaut⁵ and Filip van Den Bosch⁶, ¹Department of Rheumatology, Ghent University Hospital and VIB Ghent University, Ghent, Belgium, ²Laboratory for Molecular Immunology and Inflammation, Department of Rheumatology, Ghent University Hospital and VIB Ghent University, Ghent, Belgium, ³Department of Rheumatology, Ghent University Hospital, Ghent, 9000, Belgium, ⁴Department of Public Health, Ghent University, Ghent, Belgium, Biostatistics Unit,Ghent University, Ghent, Belgium, Ghent, Belgium, ⁵Ghent University Hospital and VIB Ghent University, Ghent, Belgium, ⁶Rheumatology, Ghent University Hospital and VIB Ghent University, Gent, Belgium
Background/Purpose: Treatment with TNFi in early stages of peripheral Spondyloarthritis (pSpA) results in higher rates of clinical remission, compared to treatment in more longstanding disease.…
Abstract Number: 16L • 2017 ACR/ARHP Annual Meeting
Incidence of Thromboembolic Events in the Tofacitinib Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis and Ulcerative Colitis Development Programs
Philip J Mease¹, Joel Kremer², Stanley Cohen³, Jeffrey R Curtis⁴, Christina Charles-Schoeman⁵, Edward V Loftus⁶, Jeffrey D Greenberg⁷, Niki Palmetto⁸, Keith S Kanik⁹, Daniela Graham⁹, Cunshan Wang⁹, Pinaki Biswas⁸, Gary Chan¹⁰, Ryan DeMasi¹⁰, Hernan Valdez⁸, Thijs Hendrikx¹⁰ and Thomas V Jones¹⁰, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY, ³Metroplex Clinical Research Center, Dallas, TX, ⁴University of Alabama, Birmingham, AL, ⁵University of California, Los Angeles, CA, ⁶Mayo Clinic, Rochester, MN, ⁷Corrona, LLC, Southborough, MA, ⁸Pfizer Inc, New York, NY, ⁹Pfizer Inc, Groton, CT, ¹⁰Pfizer Inc, Collegeville, PA

Background/Purpose: Tofacitinib is an oral Janus kinase (JAK) inhibitor that preferentially inhibits signaling by JAK3 and JAK1, with functional selectivity over JAK2. Potential increased risk…
Abstract Number: 254 • 2017 ACR/ARHP Annual Meeting
Psoriatic Arthritis Sonographic Enthesitis Scores – Systematic Review of the Literature
Ofir Elalouf¹, Sibel Bakirci², Zahi Touma³, Melanie A Anderson⁴, Gurjit S. Kaeley⁵, Sibel Z. Aydin⁶ and Lihi Eder^7,8, ¹Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ²Fellow in Rheumatology, Antalya, Turkey, ³Rheumatology, University of Toronto, Division of Rheumatology, Institute of Health Policy, Management and Evaluation, Toronto, ON, Canada, ⁴Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁵University of Florida, Ponte Vedra Beach, FL, ⁶University of Ottawa, Ottawa, ON, Canada, ⁷Medicine, University of Toronto, Toronto, ON, Canada, ⁸Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada
Background/Purpose: Enthesitis is a prominent feature of spondyloarthropathy (SpA), including psoriatic arthritis (PsA). The evaluation of enthesitis has conventionally been conducted by clinical exam, a…
Abstract Number: 629 • 2017 ACR/ARHP Annual Meeting
Is Earlier Golimumab Treatment Initiation in Psa and As Patients Associated with Improved Outcomes?
Suneil Kapur¹, Proton Rahman², Michelle Teo³, Jodie Reis⁴, Rajwinder Dhillon⁵, Pauline Boulos⁶, Raman Rai⁷, Regan Arendse⁸, Julie Vaillancourt⁹, Emmanouil Rampakakis⁹, Allen J Lehman¹⁰, Francois Nantel¹¹ and Brendan Osborne¹¹, ¹University of Ottawa, 139 Greenbank Rd, Suite 203, ON, Canada, ²Rheumatology, St Claires Mercy Hospital, St Johns, NF, Canada, ³Balfour Medical Clinic, Penticton, BC, Canada, ⁴University of Saskatchewan, Saskatoon, SK, Canada, ⁵Private Practice, Niagara Falls, ON, Canada, ⁶Private Practice, Dundas, ON, Canada, ⁷Private Practice, Hamilton, ON, Canada, ⁸University of Saskatchewan, Saskatoon, ON, Canada, ⁹JSS Medical Research, Montreal, QC, Canada, ¹⁰Janssen Inc., Toronto, ON, Canada, ¹¹Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Previous studies have suggested that treating patients earlier with biologics could improve disease outcomes. The aim of this analysis was to assess the impact…
Abstract Number: 2503 • 2017 ACR/ARHP Annual Meeting
Does Maastricht Ankylosing Spondylitis Enthesitis Scores Differ between Ankylosing Spondylitis, Psoriatic Arthritis and Rheumatoid Arthritis Patients?
Steffan Robstad Nilssen¹, Jintana B: Andersen¹, Hanne K. Vestaby¹, Glenn Haugeberg² and Brigitte Michelsen³, ¹Dept. of Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ²Martina Hansens Hospital, Bærum, Norway, ³Dept. of Rheumatology, Hospital of Southern Norway Trust, kristiansand, Norway
Background/Purpose: The Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) is an enthesitis index developed and validated as an outcome measure in ankylosing spondylitis (AS), but is…
Abstract Number: 342 • 2017 ACR/ARHP Annual Meeting
Health Related Quality of Life Is Comparable in Psoriatic Arthritis and Rheumatoid Arthritis Patients in Spite of Different Disease Activity. SF-36 Data from a Large Prospective Observational Multicentre Study
Brigitte Michelsen^1,2, Till Uhlig¹, Eirik K Kristianslund¹, Joseph Sexton¹, Elisabeth Lie¹, Karen M Fagerli³, Hilde B Hammer⁴, Glenn Haugeberg^5,6 and Tore K Kvien⁷, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Dept. of Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ³Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Dept of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁵Martina Hansens Hospital, Bærum, Norway, ⁶NTNU, Norwegian University of Science and Technology, Trondheim, Norway, ⁷Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: It is well established that RA patients have lower health related quality of life (HRQoL) across several domains compared with the general population, whereas…
Abstract Number: 631 • 2017 ACR/ARHP Annual Meeting
Predictors of Long-Term Retention of Methotrexate and Other Dmards with Golimumab in Rheumatoid Arthritis and Psoriatic Arthritis: An Analysis from a Prospective, Observational Registry
Derek Haaland¹, Anna Jaroszynska², B Haraoui³, Suneil Kapur⁴, Jacqueline Stewart⁵, Wojciech Olsynzynski⁶, Keltie Anderson⁷, Raman Rai⁸, Michael Starr⁹, Alexander Tsoukas¹⁰, Eliofotisti Psaradellis¹¹, Emmanouil Rampakakis¹¹, Cathy Tkaczyk¹², Allen J Lehman¹³, Francois Nantel¹² and Brendan Osborne¹², ¹Rheumatology, Clinical Immunology & Allergy, McMaster University, Barrie, ON, Canada, ²Private practice, Burlington, ON, Canada, ³Institut de Recherche en Rhumatologie de Montréal (IRRM), Montreal, QC, Canada, ⁴University of Ottawa, 139 Greenbank Rd, Suite 203, ON, Canada, ⁵Penticton Regional Hospital, Penticton, BC, Canada, ⁶University of Saskatchewan, Saskatoon, ON, Canada, ⁷University of Saskatchewan, Saskatoon, SK, Canada, ⁸Private Practice, Hamilton, ON, Canada, ⁹Rheumatology, McGill University, Pointe-Claire,, QC, Canada, ¹⁰McGill University, Montreal, QC, Canada, ¹¹JSS Medical Research, Montreal, QC, Canada, ¹²Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹³Janssen Inc., Toronto, ON, Canada
Background/Purpose: Previous studies have suggested that concomitant methotrexate therapy may increase the efficacy of biologic treatments. A scarcity of data exists on the benefits of…
Abstract Number: 2526 • 2017 ACR/ARHP Annual Meeting
Baseline Data from the Recent-Onset Psoriatic Arthritis Registry of the Spanish Society of Rheumatology
Rubén Queiro¹, Ana Laiz², Carlos Alberto Montilla-Morales³, Eva Galindez-Agirregoikoa⁴, Juan J. Bethencourt⁵ and Daniel Seoane⁶, ¹Rheumatology Department. Hospital Universitario Central de Asturias, Oviedo, Spain, ²Rheumatology, HU. Santa Creu i San Pau, Barcelona, Spain, ³Hospital Clínico Universitario de Salamanca, Salamanca, Spain, ⁴Rheumatology Division, Hospital Universitario de Basurto, Bilbao, Spain, ⁵Rheumatology, HU. Canarias, Sta. Cruz de Tenerife, Spain, ⁶Research Unit, Spanish Foundation of Rheumatology, Madrid, Spain
Background/Purpose: The natural history of psoriatic arthritis (PsA) is hardly known and the information regarding PsA prospective cohorts is very scarce worldwide. The information obtained…
Abstract Number: 596 • 2017 ACR/ARHP Annual Meeting
Effect of Tofacitinib on Patient-Reported Outcomes in Patients with Active Psoriatic Arthritis: Results from 2 Phase 3 Studies
Vibeke Strand¹, Kurt de Vlam², Jose A Covarrubias-Cobos³, Philip J Mease⁴, Dafna D Gladman⁵, Thijs Hendrikx⁶, Elizabeth Kudlacz⁷, Daniela Graham⁷, Joseph Wu⁷, Joseph C Cappelleri⁷ and Ming-Ann Hsu⁷, ¹Stanford University, Palo Alto, CA, ²UZ Leuven, Leuven, Belgium, ³Unidad Reumatologica Las Americas S.C.P, Yucatán, Mexico, ⁴Swedish Medical Center and University of Washington, Seattle, WA, ⁵Department of Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁶Pfizer Inc, Collegeville, PA, ⁷Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor under investigation for the treatment of psoriatic arthritis (PsA). Safety and efficacy were investigated in 2 Phase…
Abstract Number: 880 • 2017 ACR/ARHP Annual Meeting
Tofacitinib Treatment in Patients with Psoriatic Arthritis and Rates of Radiologic Progression According to Baseline CRP Levels: Results from a Phase 3 Clinical Study
Désirée van der Heijde¹, Dafna D Gladman², Oliver FitzGerald³, Arthur Kavanaugh⁴, Daniela Graham⁵, Cunshan Wang⁵ and Lara Fallon⁶, ¹Leiden University Medical Center, Leiden, Netherlands, ²Department of Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Department of Rheumatology, St Vincent's University Hospital, Dublin, Ireland, ⁴University of California San Diego School of Medicine, La Jolla, San Diego, CA, ⁵Pfizer Inc, Groton, CT, ⁶Pfizer Canada, Montreal, QC, Canada
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor under investigation for the treatment of psoriatic arthritis (PsA). Here, we evaluate radiographic progression in PsA patients…
Abstract Number: 2536 • 2017 ACR/ARHP Annual Meeting
Comparison of Quality-of-Life, Function and Psoriasis Measures in Minimal Disease Activity and DAS28 States in Routine Care of Patients with Psoriatic Arthritis
Catherine Hughes, Nora Ng, Toby Garrood and Bruce Kirkham, Rheumatology, Guy's & St Thomas NHS Foundation Trust, London, United Kingdom
Background/Purpose: Psoriatic arthritis (PsA) often occurs with skin psoriasis (PsO). Disease activity can be measured using several tools including Minimal Disease Activity (MDA/VLMDA) or 28…
Abstract Number: 600 • 2017 ACR/ARHP Annual Meeting
Low Rates of Major Adverse Cardiac Events, Malignancies, and Serious Infections in Subjects with Psoriasis and Psoriatic Arthritis Treated with Apremilast for ≥156 Weeks: Pooled Analysis from the Esteem and Palace 1-3 Phase 3 Trials
Arthur Kavanaugh¹, Matthias Augustin², Eric Lespessailles³, Kim A. Papp⁴, Maria Paris⁵, Rongdean Chen⁵, Dafna D Gladman⁶, David M. Pariser⁷ and Ketty Peris⁸, ¹University of California, San Diego, School of Medicine, La Jolla, CA, ²Institute for Health Care Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf, Hamburg, Germany, ³University of Orleans, Orleans, France, ⁴Probity Medical Research, Waterloo, ON, Canada, ⁵Celgene Corporation, Summit, NJ, ⁶Toronto Western Hospital, Toronto, ON, Canada, ⁷Eastern Virginia Medical School and Virginia Clinical Research, Inc., Norfolk, VA, ⁸Catholic University of Rome, Rome, Italy
Background/Purpose: Apremilast (APR), an oral PDE4 inhibitor, was effective in phase 3, randomized, placebo (PBO)-controlled trials assessing treatment of moderate to severe plaque psoriasis (ESTEEM…
Abstract Number: 884 • 2017 ACR/ARHP Annual Meeting
Changes in Lipid Levels and Incidence of Cardiovascular Events Following Tofacitinib Treatment in Patients with Psoriatic Arthritis: An Integrated Analysis across Phase 3 and Long-Term Extension Studies
Dafna D Gladman¹, Christina Charles-Schoeman², Iain B. McInnes³, Douglas J. Veale⁴, Bruce Thiers⁵, Daniela Graham⁶, Cunshan Wang⁶, Thomas Jones⁷, Robert Wolk⁶ and Ryan DeMasi⁷, ¹Department of Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of California, Los Angeles, Los Angeles, CA, ³Glasgow Biomedical Research Centre, University of Glasgow, Glasgow, United Kingdom, ⁴St. Vincent’s University Hospital and University College Dublin, Dublin, Ireland, ⁵Medical University of South Carolina, Charleston, SC, ⁶Pfizer Inc, Groton, CT, ⁷Pfizer Inc, Collegeville, PA
Background/Purpose: Cardiovascular (CV) disease and cardiometabolic syndrome are common comorbidities/causes of mortality in patients (pts) with psoriatic arthritis (PsA). Tofacitinib is an oral Janus kinase…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].